Pancreas News and Research RSS Feed - Pancreas News and Research

The pancreas is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland producing several important hormones, including insulin, glucagon, and somatostatin, as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme.
Scientists develop implantable 'artificial pancreas' to help control blood sugar in diabetes patients

Scientists develop implantable 'artificial pancreas' to help control blood sugar in diabetes patients

Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the ACS journal Industrial & Engineering Chemistry Research the development of an implantable "artificial pancreas" that continuously measures a person's blood sugar, or glucose, level and can automatically release insulin as needed. [More]
SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. [More]
IU researchers find that microRNA-29 may be potent therapeutic target against pancreatic cancer

IU researchers find that microRNA-29 may be potent therapeutic target against pancreatic cancer

Indiana University cancer researchers found that a particular microRNA may be a potent therapeutic agent against pancreatic cancer. The research was published June 22 in the journal Scientific Reports. [More]
Perle Bioscience announces enrollment for Phase 3 trial of combination therapy in type 1 diabetics

Perle Bioscience announces enrollment for Phase 3 trial of combination therapy in type 1 diabetics

Perle Bioscience, Inc. announces enrollment for the Insulin Independence Trial (IIT). This trial is the first and only Phase 3 trial to test a combination therapy in type 1 diabetics. [More]
Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), concludes that a blood clot in an abdominal vein may be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. [More]
AstraZeneca, Inserm to investigate new therapeutic approaches to type 2 diabetes, CKD

AstraZeneca, Inserm to investigate new therapeutic approaches to type 2 diabetes, CKD

AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches totype 2 diabetes and Chronic Kidney Disease. [More]
Rare form of autoimmune syndrome may be tied to mutations in AIRE gene

Rare form of autoimmune syndrome may be tied to mutations in AIRE gene

A hereditary autoimmune disease that was thought to be exceedingly rare may have a less severe form that affects one in 1,000 people or even more, according to new research conducted at the Weizmann Institute of Science, in Israel, and the University of Bergen, in Norway. [More]
Understanding crosstalk between cells in the pancreas can help treat diabetes

Understanding crosstalk between cells in the pancreas can help treat diabetes

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk is between the cells that control your body's response to sugar, and understanding the conversation can help us understand, and perhaps ultimately treat, diabetes. [More]
Scientists report that mouse with weak bones appears to have strong metabolism

Scientists report that mouse with weak bones appears to have strong metabolism

One mouse with weak bones appears to have a strong metabolism, even on a high-fat diet, scientists report. While weaker bones are clearly not a good thing, scientists suspect that, somewhere in the conversation between the genetically engineered mouse's skeleton and the rest of its body, there may be an answer that helps obese individuals avoid some of the worst ravages of this health epidemic. [More]
Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

A Montréal research team, co-supervised by Dr. Rémi Rabasa-Lhoret from the IRCM and Dr. Laurent Legault from the Montreal Children's Hospital, undertook the first paediatric outpatient study to compare three alternative treatments for type 1 diabetes. [More]
Catalan researchers first to use liposomes to fight against diabetes

Catalan researchers first to use liposomes to fight against diabetes

For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work. [More]
Researchers pinpoint gene that may solve the root cause of diabetes

Researchers pinpoint gene that may solve the root cause of diabetes

Professor Jeffery Tessem has pinpointed a gene that may help solve a riddle at the root of diabetes, the high-blood-sugar disease affecting 400 million people worldwide. [More]
Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events. [More]
Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund. [More]
BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Type 1 diabetes, which usually appears in children and adolescents, affects over 30 million people worldwide. Resulting from an auto-immune reaction that destroys the pancreatic beta cells that produce insulin, the disease leads to pathologically high levels of sugar in the blood and urine, resulting in high rates of morbidity and mortality. The current treatment for Type 1 diabetes is lifetime administration of insulin by injection. [More]
Houston Methodist Hospital and MD Anderson Cancer Center surgeons successfully perform multi-organ transplant

Houston Methodist Hospital and MD Anderson Cancer Center surgeons successfully perform multi-organ transplant

Surgical teams from Houston Methodist Hospital and The University of Texas MD Anderson Cancer Center successfully transplanted, for the first time, a scalp and skull while performing kidney and pancreas transplants. [More]
Understanding link between polycystic ovary syndrome and diabetes

Understanding link between polycystic ovary syndrome and diabetes

Nearly 50 percent of women with polycystic ovary syndrome (PCOS) develop pre-diabetes or type 2 diabetes before the age of 40, but the reasons for the correlation was unclear. In a new study in the American Journal of Physiology-Endocrinology and Metabolism, researchers report that inflammation is the cause for the increased diabetes risk in women with PCOS. [More]
El Camino Hospital enrolls first patient in safety study using RenovoCath

El Camino Hospital enrolls first patient in safety study using RenovoCath

El Camino Hospital in Mountain View, California has enrolled the first patient in a safety study using the RenovoCath, a new catheter that is being introduced for targeted delivery of fluids to selected sites in the peripheral vascular system. The study will help physicians determine appropriate dosing of locally-delivered chemotherapy for patients with pancreatic cancer. [More]
Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer. [More]
PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine, Inc. today announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. [More]
Advertisement
Advertisement